Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

  • Showing results for genbaku ge. Search instead for Genbatu Ge (0)
1.

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.

Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S.

Nat Commun. 2019 Jan 16;10(1):259. doi: 10.1038/s41467-018-08074-0.

2.

Evaluation of FilmArray respiratory panel multiplex polymerase chain reaction assay for detection of pathogens in adult outpatients with acute respiratory tract infection.

Kaku N, Hashiguchi K, Iwanaga Y, Akamatsu N, Matsuda J, Kosai K, Uno N, Morinaga Y, Kitazaki T, Hasegawa H, Miyazaki T, Fukuda M, Izumikawa K, Mukae H, Yanagihara K.

J Infect Chemother. 2018 Sep;24(9):734-738. doi: 10.1016/j.jiac.2018.05.006. Epub 2018 Jun 9.

PMID:
29895452
3.

Chromosomal analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki.

Horai M, Satoh S, Matsuo M, Iwanaga M, Horio K, Jo T, Takasaki Y, Kawaguchi Y, Tsushima H, Yoshida S, Taguchi M, Itonaga H, Sawayama Y, Taguchi J, Imaizumi Y, Hata T, Moriuchi Y, Haase D, Yoshiura KI, Miyazaki Y.

Br J Haematol. 2018 Feb;180(3):381-390. doi: 10.1111/bjh.15050. Epub 2017 Dec 19.

PMID:
29265181
4.

A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).

Akiyoshi K, Hamaguchi T, Yoshimura K, Takahashi N, Honma Y, Iwasa S, Takashima A, Kato K, Yamada Y, Onodera H, Takeshita S, Yasui H, Sakai G, Akatsuka S, Ogawa K, Horita Y, Nagai Y, Shimada Y.

Clin Colorectal Cancer. 2018 Mar;17(1):e83-e89. doi: 10.1016/j.clcc.2017.10.004. Epub 2017 Oct 16.

PMID:
29169974
5.

Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).

Fukuda M, Shimada M, Kitazaki T, Nagashima S, Hashiguchi K, Ebi N, Takayama K, Nakanishi Y, Semba H, Harada T, Seto T, Okamoto I, Ichinose Y, Sugio K.

Thorac Cancer. 2017 Jan;8(1):40-45. doi: 10.1111/1759-7714.12407. Epub 2016 Nov 24.

6.

Germline mutations causing familial lung cancer.

Tomoshige K, Matsumoto K, Tsuchiya T, Oikawa M, Miyazaki T, Yamasaki N, Mishima H, Kinoshita A, Kubo T, Fukushima K, Yoshiura K, Nagayasu T.

J Hum Genet. 2015 Oct;60(10):597-603. doi: 10.1038/jhg.2015.75. Epub 2015 Jul 16.

PMID:
26178433
7.

Sweet's syndrome in patients with MDS and MEFV mutations.

Jo T, Horio K, Migita K.

N Engl J Med. 2015 Feb 12;372(7):686-8. doi: 10.1056/NEJMc1412998. No abstract available.

PMID:
25671271

Supplemental Content

Loading ...
Support Center